5-Question Quiz on Immunotherapy in Melanoma

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.

AI Model May Predict Immunotherapy Responses in Advanced NSCLC

In patients with low-grade intermediate-risk non-muscle invasive bladder cancer who achieved a CR at 3 months with UGN-102, the 18-month DOR was 80.6%.

Related Content

Russ Conroy

Oncologists Reflect on Pandemic's Lasting Impact on Cancer Care

Use of Deep-IO may help refine treatment precision and identify patients with advanced NSCLC who are likely to benefit from immune checkpoint inhibitors.

Aditya Bardia, MD, MPH;Ritu Salani, MD;Scarlett Lin Gomez, PhD;Marwan G. Fakih, MD;Elizabeth Ren Zhang-Velten, MD, PhD;Frances Chow, MD;James B. Yu, MD, MHS, FASTRO

March 10th 2025

A World of Research, Care, and Science: Becoming A Radiation Oncologist

Hear from leading cancer experts about the lasting impact the COVID-19 pandemic has left on clinical practice.

Traversing the Complexities of Non-Clear Cell Renal Cell Carcinoma

James B. Yu, MD, MHS, FASTRO, didn’t always envision himself as a radiation oncologist, but now works tirelessly to treat patients and advance research for genitourinary cancers.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Stephanie A. Berg, DO

March 7th 2025

The Rapid Evolution of Cardiotoxicity in Breast Cancer and Why More Data is Needed

A brief overview of the current RCC landscape was provided in the most recent Oncology Decoded podcast.

UGN-102 Yields Enduring 18-Month Responses in Low-Grade NMIBC

Despite a relatively small, though increasing, level of focus in oncology, radiation-induced heart damage in breast cancer is a relevant clinical problem that needs more attention.